Polymyalgia Rheumatica Prednisolone Dosing
Start with 12.5-25 mg prednisolone daily, with most patients responding well to 15 mg/day, then taper to 10 mg within 4-8 weeks, followed by 1 mg reductions every 4 weeks until discontinuation. 1
Initial Dosing Strategy
The 2015 EULAR/ACR guidelines provide clear dosing parameters that balance efficacy against glucocorticoid toxicity 1:
- Starting dose range: 12.5-25 mg prednisolone equivalent daily
- Avoid doses ≤7.5 mg/day (conditionally discouraged - insufficient efficacy)
- Never exceed 30 mg/day (strongly contraindicated - no added benefit, increased harm)
Tailoring the Initial Dose Within This Range
Choose higher end (20-25 mg) when:
- High risk of relapse (female sex, ESR >40 mm/hr, peripheral inflammatory arthritis) 1
- Low risk of glucocorticoid adverse effects
- No significant comorbidities
Choose lower end (12.5-15 mg) when:
- Diabetes, osteoporosis, or glaucoma present 1
- Other glucocorticoid-related risk factors exist
- Lower body weight (dose correlates with weight, approximately 0.19 mg/kg for responders) 2
Research supports that 12.5 mg is sufficient in approximately 78% of patients, particularly those with lower body weight 2. The 15 mg dose appears optimal for most patients, achieving remission while minimizing cumulative glucocorticoid exposure 3.
Tapering Protocol
The tapering schedule follows three distinct phases 1:
Phase 1: Initial Rapid Taper (Weeks 0-8)
- Reduce from starting dose to 10 mg/day within 4-8 weeks
- Expect clinical improvement within 2 weeks; near-complete response by 4 weeks 1
Phase 2: Slow Maintenance Taper (After achieving remission)
- Reduce by 1 mg every 4 weeks (or 1.25 mg decrements using alternate-day schedules like 10/7.5 mg)
- Continue until complete discontinuation if remission maintained 1
- Tapering slower than 1 mg/month reduces relapse rates significantly 3
Phase 3: Relapse Management
- If relapse occurs: increase to pre-relapse dose
- Taper back down to the relapse dose over 4-8 weeks
- Then resume 1 mg/4-week reductions 1
Administration Details
- Single daily dose preferred over divided doses 1
- Exception: Consider split dosing only for prominent night pain when tapering below 5 mg/day 1
Alternative: Intramuscular Methylprednisolone
For patients with adherence concerns or oral intolerance 1:
- Starting: 120 mg IM every 3 weeks for first 9 weeks
- Week 12: 100 mg IM, then monthly
- Reduce by 20 mg every 12 weeks until week 48
- Then reduce by 20 mg every 16 weeks until discontinuation
Glucocorticoid-Sparing Strategy
Consider adding methotrexate 7.5-10 mg/week orally when 1:
- High relapse risk (female, high ESR, peripheral arthritis)
- Significant comorbidities (diabetes, osteoporosis, glaucoma)
- Relapse on tapering
- Glucocorticoid-related adverse events develop
Recent evidence suggests MTX allows earlier glucocorticoid discontinuation, with 66% achieving steroid-free remission at 26 weeks 4.
Monitoring Schedule
1:
- First year: Every 4-8 weeks
- Second year: Every 8-12 weeks
- More frequently during tapering or if relapse suspected
- Monitor for disease activity, inflammatory markers, and adverse events at each visit
Critical Pitfalls to Avoid
- Starting >30 mg/day: No evidence of benefit; clear evidence of harm from high-dose glucocorticoids 1
- Rapid tapering: Reductions faster than 1 mg/month increase relapse risk 2.4-5.3 fold 5
- Starting <7.5 mg/day: Insufficient for most patients, leads to inadequate disease control 1
- Initiating prednisolone before specialist evaluation: Makes subsequent clinical assessment extremely difficult, with sensitivity dropping from 85.9% to 3.5% 6
When Initial Dose Fails
If insufficient improvement within 2 weeks 1:
- Increase oral dose up to 25 mg prednisolone equivalent
- If using IM methylprednisolone, consider switching to oral glucocorticoids
- Re-evaluate diagnosis if requiring doses >30 mg 1
The key principle: individualize within the 12.5-25 mg range based on relapse risk versus adverse event risk, then taper slowly at 1 mg every 4 weeks once at 10 mg/day.